Oral Spironolactone
$33.00
Per month
Each bottle is a 3-month supply, billed at $99.00.
Noticing thinner hair? There’s a hormonal explanation and a prescription solution. Oral Spironolactone is a daily pill that can prevent further hair thinning in up to 100% of women with female-pattern hair loss.* It's safest and most effective for women with signs of excess androgens.
Includes $0 unlimited doctor access
Delivered to your door for free
HSA/FSA Eligible
FDA Approved
Hair loss is common in menopause. But you don’t have to accept it.
Targets hormonal hair loss
Prevents thinning hair
Fits your needs
Doctor-prescribed
Learn more about Oral Spironolactone
What is it: Spironolactone is a daily prescription tablet that can help reduce hair loss during menopause. It’s an anti-androgen that works to combat a key hormonal signal behind hair thinning: excess androgens.
Who is it for: Women who have thinning hair related to hormones, particularly when it occurs alongside signs of higher androgen levels — such as unwanted hair growth on the face or body, persistent hormonal acne, or a diagnosis of polycystic ovary syndrome (PCOS). It can be appropriate as well if you've developed unwanted hair growth after starting minoxidil, or if minoxidil alone hasn't given you the results you were hoping for and you're looking for an additional option.
What am I getting: 90 tablets (3-month supply) of oral spironolactone.
How to get it: Prescription required. A menopause-specialized doctor will review your medical history to determine if this is the right treatment for you.
THE TRUTH ABOUT MENOPAUSE
Almost 40% of women will experience hair loss during and after menopause
Frequently asked questions
The Alloy Promise
At Alloy Health, we believe every woman deserves thoughtful, evidence-based care, and the information she needs to make confident decisions about her health based on facts, not fear.
Our board-certified physicians follow guidelines from leading medical organizations including ACOG and The Menopause Society and recommend treatments tailored to each patient.
Learn more
Disclosure
*Rathnayake & Sinclair, Dermatol Clin, 2010.
**Famenini et al., JAAD, 2015